These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 9616891)

  • 61. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
    Wolff JM; Fandel T; Borchers H; Brehmer B; Jakse G
    Br J Urol; 1998 Mar; 81(3):403-5. PubMed ID: 9523660
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
    Marks LS; Dorey FJ; Rhodes T; Shery ED; Rittenhouse H; Partin AW; deKernion JB
    J Urol; 1996 Sep; 156(3):1035-9. PubMed ID: 8709302
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
    Sardana G; Diamandis EP
    Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reference range of prostate-specific antigen after transurethral resection of the prostate.
    Aus G; Bergdahl S; Frösing R; Lodding P; Pileblad E; Hugosson J
    Urology; 1996 Apr; 47(4):529-31. PubMed ID: 8638362
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
    Cooke RR; Nacey JN; Beeston RE; Delahunt B
    N Z Med J; 1992 Sep; 105(941):345-7. PubMed ID: 1279493
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.
    Carter HB; Pearson JD; Waclawiw Z; Metter EJ; Chan DW; Guess HA; Walsh PC
    Urology; 1995 Apr; 45(4):591-6. PubMed ID: 7536366
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities.
    Orihuela E; Kocurek JN; Warren MM
    Arch Esp Urol; 1997 Sep; 50(7):821-4. PubMed ID: 9350090
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Established oneself the detection of serum prostate specific antigen and application in clinical practice].
    Feng T; Dou CQ; Xia TL
    Zhonghua Wai Ke Za Zhi; 1994 Nov; 32(11):685-7. PubMed ID: 7539736
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
    Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
    Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
    Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bladder catheterization and a plasma prostate-specific antigen in patients with benign prostatic hyperplasia and complete urine retention.
    Dutkiewicz S; Stepień K; Witeska A
    Mater Med Pol; 1995; 27(2):71-3. PubMed ID: 8935194
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen].
    Machida T; Ohishi Y; Wada T; Akimoto S; Shimazaki J; Oda H; Yokoyama M; Tsukada T; Nakayama T; Akiyama A
    Hinyokika Kiyo; 1993 Oct; 39(10):977-84. PubMed ID: 7505519
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia.
    Ellis WJ; Brawer MK
    Urol Clin North Am; 1993 Nov; 20(4):621-5. PubMed ID: 7505969
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
    Rodríguez Duarte C; Aguillón J; Rodríguez H
    Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
    Hall MC; Roehrborn CG; McConnell JD
    Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical evaluation of TANDEM PSA in Japanese cases and comparison with other methods].
    Kuriyama M; Yamamoto N; Shinoda I; Kawada Y; Akimoto S; Shimazaki J
    Hinyokika Kiyo; 1995 Jan; 41(1):39-46. PubMed ID: 7534972
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prostate specific antigen. Experimental and clinical observations.
    Huber PR; Schnell Y; Hering F; Rutishauser G
    Scand J Urol Nephrol Suppl; 1987; 104():33-9. PubMed ID: 2449722
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prostate cancer detection in BPH patients.
    Puppo P; Perachino M; Ricciotti G; Bozzo W
    Arch Esp Urol; 1994 Nov; 47(9):867-72. PubMed ID: 7530942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.